Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

New research at the Kennedy Institute reveals potential of a novel class of drugs for the treatment of rheumatoid arthritis.

cIAP inhibitors restore a healthy balance between inflammatory and regulatory T lymphocytes to reduce inflammatory arthritis

Publications

Trials

Events

Ad-hoc studentships

Oxford Trauma

Research groups

Clinical Kennedy Trust Prize Studentships

Applications for these projects are now closed. Please visit the website in summer 2026 to see available projects for October 2027 entry.

SITU

Forms library

Files Library

Study with us

Botnar projects

Applications for these projects are now closed. Please visit the website in summer 2026 to see available projects for October 2027 entry.

About us

OPEN ARMS

Jobs

Trials in closure

Trials in follow up

Trials under analysis

Trials open to recruitment

Trials in set-up

Load More

Meet the team

Read the paper

cIAP1/2 inhibition synergizes with TNF inhibition in autoimmunity by down-regulating IL-17A and inducing Tregs

Scientific Advances 2019

Full paper

Read more

Two targets are better than one 

Nature Reviews Rheumatology

Read the paper

Anti-TNF Drugs

Find out more about

Similar stories